A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

Also called NCT04218734

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 214 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04218734
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04218734. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-14 (actual); primary completion 2021-06-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
DBPR108
Intervention (Drug)
metformin hydrochloride
Intervention (Drug)
placepo
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04218734
Content hash
87ebb15f00fb20ec2ad9226d91750d6ac7e014390311d1d596b15a16c8897833